Generated by All in One SEO v4.9.7.2, this is an llms.txt file, used by LLMs to index the site.

# APY Therapeutics

## Sitemaps

- [XML Sitemap](https://apytherapeutics.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Hello world!](https://apytherapeutics.com/hello-world/) - Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

## Pages

- [Home](https://apytherapeutics.com/) - APY TherapeuticsAPY Therapeutics LLC is developing arylmyxopyronins--APYs--as novel first-in-class IV-oral treatments for lower-respiratory-tract infections caused by drug-resistant and multi-drug-resistant Gram-negative bacteria, Gram-positive bacteria, and respiratory atypicals.
- [Our Pipeline](https://apytherapeutics.com/projects/) - Our Pipeline​ APY-GNGPs We have identified novel orally available arylmyxopyronins--APY-GNGPs--that exhibit potent in vitro activity against Acinetobacter, Burkholderia, and the full set of Gram-positive bacterial pathogens and respiratory atypicals relevant to lower-respiratory-tract infections, including drug-resistant and multi-drug-resistant isolates.Our current APY-GNGPs exhibit in vitro coverage and potency against Acinetobacter and Burkholderia superior to the current IV
- [News](https://apytherapeutics.com/news/) - News July 9, 2025 APY Therapeutics is pleased to announce it has received a Catalyst Research and Development Voucher Award from the New Jersey Commission on Science, Innovation, and Technology. The award will fund mouse MRSA lung infection dose-escalation efficacy studies of APY-GNGPs for candidate selection. July 3, 2025 PCT patent application PCT/US24/61654 (filed December
- [Contact Us](https://apytherapeutics.com/contact-us/) - Contact Us​ Email info@APYTherapeutics.com Mail APY Therapeutics, LLC, North Brunswick NJ 08902, USA LinkedIn https://www.linkedin.com/company/apy-therapeutics-llp X/Twitter https://x.com/APYTherapeutics
- [About Us](https://apytherapeutics.com/about/) - About Us RICHARD H. EBRIGHT, PH.D. (FOUNDER, CEO)Laboratory Director, Waksman Institute, Rutgers; 1987-Board of Governors Professor, Chemistry, Rutgers; 2013-Investigator, Howard Hughes Medical Institute; 1997-2013Asst. Professor to Dist. Professor, Chemistry, Rutgers; 1987-2013Ph.D., Microbiology and Molecular Genetics, Harvard; 198620 years research on antibacterial drug discovery185 publications; 46 issued patents DAVID DEGEN, PH.D. (CSO, DIRECTOR-MICROBIOLOGY)Research Associate, Rutgers; 2017-Graduate

## Categories

- [Uncategorized](https://apytherapeutics.com/category/uncategorized/)